Cancer Drug Promising for Alzheimer's Disease

In a small phase 2 trial, GM-CSF/sargramostim provided measurable disease-modifying and memory-enhancing benefits in patients with mild-to-moderate Alzheimer’s disease.
Medscape Medical News

Source link

Comments are closed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy